Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

711424.pdf (2.53 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-03-15

Llicència de publicació

cc-by-nc-nd (c) Guiteras, Jordi et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178677

The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.omtn.2021.03.019

Resum

Systemic lupus erythematosus is a highly complex and hetero- geneous autoimmune disease mostly mediated by B cells. It is characterized by circulating self-reactive antibodies that depo- sit and form immune complexes in kidney, leading to irrepa- rable tissue damage and resulting in lupus nephritis. In a New Zealand Black X New Zealand White F1 mouse model, we tested two different small interfering RNA (siRNA) silencing treatments against interferon regulatory factor 5 (IRF5) and B cell-activating factor (BLYSS) expression and their combination in a second set of animals. The administra- tion of these two siRNAs separately prevented the progression of proteinuria and albuminuria at similar levels to that in cyclo- phosphamide animals. These treatments effectively resulted in a reduction of serum anti-double-stranded DNA (dsDNA) an- tibodies and histopathological renal score compared with non- treated group. Treated groups showed macrophage, T cell, and B cell infiltrate reduction in renal tissue. Moreover, kidney gene expression analysis revealed that siRNA treatments modulated very few pathways in contrast to cyclophosphamide, despite showing similar therapeutic effects. Additionally, the com- bined therapy tested in a second set of animals, in which the disease appeared more virulent, exhibited better results than monotherapies in the disease progression, delaying the disease onset and ameliorating the disease outcome. Herein, we pro- vide the potential therapeutic effect of both selective IRF5 and BLYSS silencing as an effective and potential treatment, particularly in early phases of the disease.

Matèries

Lupus eritematós, Malalties autoimmunitàries, Cèl·lules B

Matèries (anglès)

Lupus erythematosus, Autoimmune diseases, B cells

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GUITERAS, Jordi, et al. The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis. Molecular Therapy-Nucleic Acids. 2021. Vol. 24, num. 807-821. ISSN 2162-2531. [consulted: 9 of August of 2026]. Available at: https://hdl.handle.net/2445/178677

Exportar metadades

JSON - METS

Compartir registre